Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$55.92 USD

55.92
2,846,383

+0.12 (0.22%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $55.90 -0.02 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Why Is United Therapeutics (UTHR) Up 3.8% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day

CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day.

Brian Bolan headshot

Bear Of The Day: Catalent (CTLT)

Earnings estimates have slipped for this stock following the most recent earnings miss.

Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut

Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.

Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates

Catalent (CTLT) delivered earnings and revenue surprises of -38.18% and 4.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More

MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.

Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?

Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.

United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Catalent (CTLT) to Report a Decline in Earnings: What to Look Out for

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for October 14th

AHEXY, BLWYY, and CTLT have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2022.

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

JAZZ vs. CTLT: Which Stock Is the Better Value Option?

Why Is Catalent (CTLT) Down 18.5% Since Last Earnings Report?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?

Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward.

Company News for Aug 30, 2022

Companies in The News Are: HTHT,CTLT,MRNA,BA,UPS

Catalent (CTLT) Q4 Earnings Beat Estimates, Revenues Lag

Catalent's (CTLT) robust performance across most of its segments drives its fourth-quarter fiscal 2022 top line.

Catalent (CTLT) Q4 Earnings Surpass Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 3.48% and 0.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?

Catalent's (CTLT) Q4 results are likely to have been driven by robust segmental performances.

Here's Why You Should Hold on to Catalent (CTLT) Stock Now

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue Estimates

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -110.71% and 63.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Impel Pharmaceuticals Inc. (IMPL) Reports Q2 Loss, Tops Revenue Estimates

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 3.54% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -30.65% and 75.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?